Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2011-03-22
2011-03-22
Wilson, James O (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C544S395000
Reexamination Certificate
active
07910734
ABSTRACT:
Salts and crystals of 1-cyclopropylmethyl-4-[2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine have excellent cell adhesion inhibitory action and cell infiltration inhibitory action, and are useful as therapeutic or prophylactic agents for various inflammatory diseases and autoimmune diseases associated with adhesion and infiltration of leukocytes, such as inflammatory bowel disease (particularly ulcerative colitis or Crohn's disease), irritable bowel syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, asthma and atopic dermatitis.
REFERENCES:
patent: 5244901 (1993-09-01), George et al.
patent: 2004/0092507 (2004-05-01), Biggers et al.
patent: 2005/0261291 (2005-11-01), Kawahara et al.
patent: 0748800 (1996-12-01), None
patent: 1 698 620 (2006-09-01), None
patent: 1 832 580 (2007-09-01), None
patent: 5-186434 (1993-07-01), None
patent: 2003-506377 (2003-02-01), None
patent: 2003-192673 (2003-07-01), None
patent: 2004-523529 (2004-08-01), None
patent: WO-93/11117 (1993-06-01), None
patent: WO-01/09138 (2001-02-01), None
patent: WO-02/18320 (2002-03-01), None
patent: WO-02/059108 (2002-08-01), None
patent: WO-03/033466 (2003-04-01), None
patent: WO-03/089410 (2003-10-01), None
patent: WO-2005/005382 (2005-01-01), None
patent: WO 2005/063705 (2005-07-01), None
patent: WO-2005/063705 (2005-07-01), None
Cowart et al., “Discovery of 2-(4-Pyridin-2-yl piperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a Dopaminergic Agent with a Novel Mode of Action for the Potential Treatment of Erectile Disfunction,” Journal of Medicinal Chemistry, vol. 47, No. 15, 2004, pp. 3853-3864.
Podolsky et al., “Inflammatory Bowel Disease,” N. Engl. J. Med., vol. 347, No. 6, 2002, pp. 417-429.
Ghosh et al., “Natalizumab for active Crohn's disease,” N. Engl. J. Med., vol. 348, No. 1, 2003, pp. 24-32.
Shimoyama et al., “Granulocyte adsorption therapy in active period of ulcerative colitis,” Japanese Journal of Apheresis, vol. 18, No. 1, 1999, pp. 117-131.
Sweeney et al., “Rheumatoid arthritis,” Int. J. Biochem. Cell. Biol., vol. 36, 2004. pp. 372-378.
Lebwohl, “Psoriasis,” Lancet Neurology, vol. 361, 2003, pp. 1197-1204.
Polman et al., “New and emerging treatment options for multiple sclerosis,” Lancet Neurology, vol. 2, 2003, pp. 563-566.
Rosenwasser, “The role of T lymphocytes in the pathogenesis of asthma,” J. Allergy Clin. Immunol., vol. 111, No. 3, 2003, pp. 450-463.
Schon et al., “The molecular basis of lymphocyte recruitment to the skin,” J. Invest. Dermatol., vol. 121, No. 5, 2003, pp. 951-962.
Barbara et al., “A role for inflammation in irritable bowel syndrome,” Gut., vol. 51, Suppl. 1, 2002, pp. 41-44.
Fleming, Ian et al., “Two New Oxindole Syntheses†” Journal of the Chemical Society, Perkin Transactions 1, 1986, pp. 349-359.
Communication mailed Oct. 5, 2009 in corresponding European application No. 06746829.8.
Kotake Makoto
Osada Katsunobu
Yoneda Naoki
Birch & Stewart Kolasch & Birch, LLP
EISAI R&D Management Co., Ltd.
Leeser Erich A
Wilson James O
LandOfFree
Crystal and salt of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystal and salt of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystal and salt of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2756420